# Autolus Therapeutics plc (AUTL) Stock Price, News & Analysis
Canonical URL: https://biopharmsignal.com/company/AUTL
## Company Profile
- Ticker: AUTL
- Exchange: NASDAQ
- Sector: Biopharma
- Location: United Kingdom
- Tags: Oncology
## Stock Data
- Close: 1.9 USD
- Market cap: 465750750.5 USD
- Last updated: 2026-08-05
## Business Overview
### Programmable T-Cell Therapy Company
Autolus Therapeutics develops, manufactures, and commercializes next-generation T-cell therapies for cancer and autoimmune disease using modular cell-programming technologies.
### AUCATZYL
AUCATZYL, or obecabtagene autoleucel, is an autologous CD19 CAR T-cell therapy commercialized for adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia.
### Fast Off-Rate CAR Design
Obe-cel uses a fast off-rate CD19 binding domain intended to reduce excessive T-cell activation while preserving antitumor activity and persistence.
### Integrated Manufacturing
Autolus controls manufacturing and product delivery, supporting launches in the United States and United Kingdom and providing infrastructure for additional cell-therapy programs.
### Pipeline Expansion
The company is extending its T-cell platform into additional hematologic cancers and autoimmune disease while building on physician experience with obe-cel.
## Why The Stock Is Moving

As of Aug 5, 2026, AUTL closed down 2.56% at $1.90. No new same-company headline was identified in the current news window.

## Future Catalysts

- Autolus’s next catalyst is AUCATZYL commercial launch execution and any follow-on CAR-T update that proves the franchise can scale. The market is watching whether the cell-therapy rollout can translate into durable adoption.

## Recent News
- 2026-08-03 20:05 EST — [Autolus Therapeutics to Report Second Quarter 2026 Financial Results and Host Conference Call on August 11, 2026](https://biopharmsignal.com/news/AUTL/autolus-therapeutics-to-report-second-quarter-2026-financial-results-and-host-co-312b2ce2) — Source: Autolus Therapeutics plc
- 2026-08-03 11:13 EST — [Autolus Therapeutics Reports Preliminary Second Quarter 2026 Net Product Revenue and Announces Credit Facility of up to $250 Million with Perceptive Advisors](https://biopharmsignal.com/news/AUTL/autolus-therapeutics-reports-preliminary-second-quarter-2026-net-product-revenue-9b30030a) — Source: Autolus Therapeutics plc
- 2026-07-01 20:05 EST — [Autolus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/AUTL/autolus-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635--c43a8fbe) — Source: Autolus Therapeutics plc
- 2026-06-25 11:00 EST — [Autolus Therapeutics to Participate in Upcoming Investor Conference](https://biopharmsignal.com/news/AUTL/autolus-therapeutics-to-participate-in-upcoming-investor-conference-ec70e012) — Source: Autolus Therapeutics plc
- 2026-06-12 08:00 EST — [Autolus Therapeutics Receives Prix Galien UK Award](https://biopharmsignal.com/news/AUTL/autolus-therapeutics-receives-prix-galien-uk-award-395b0660) — Source: Autolus Therapeutics plc